AUTHORS
Christopher Schorr, BS, BSc, Parvathi Sudha2, Lindsey James3, Kelvin Lee, MD4, Attaya Suvannasankha, MD5, Travis S Johnson, Ph.D.6
AFFILIATIONS
1 Indiana University School of Medicine, Indianapolis, United States
2 Indiana University School of Medicine, Indianapolis, United States
3 UNC Eshelman School of Pharmacy, Chapel Hill, United States
4 Indiana University School of Medicine, Indianapolis, United States
5 Indiana University School of Medicine, Indianapolis, United States
6 Indiana University School of Medicine, Indianapolis, United States
ABSTRACT
Introduction: Multiple myeloma (MM) is a malignancy of clonal plasma cells that, despite substantial therapeutic advances continues to have high relapse rates. Current treatment strategies are largely centered around autologous stem cell transplant (ASCT), proteasome inhibitors (PI), immunomodulatory drugs (IMiD), monoclonal antibodies (mAb), T-cell engagers (TCE), and chimeric antigen receptor T-cell receptor (CAR-T) therapy. Antigen-directed approaches have significantly improved outcomes, yet most patients eventually relapse, often with acquired resistance to backbone agents such as bortezomib. For these reasons, agents that restore sensitivity to established backbone therapies in relapsed/refractory MM are needed.
To address this, we recently combined a large-scale single cell multiomic atlas with deep learning to identify myeloma subpopulations associated with progression and treatment resistance. This analysis identified PHF19, a PRC2 accessory subunit, as a progression associated marker in patients who have relapsed on PI and IMiD therapy. PHF19 expression is correlated with 1q gain/amplification and is likely regulated via the transcription factor PBX1 located on 1q. In time-series myeloma samples, cells expressing PHF19 showed sustained expansion during progression. All of these findings, make PHF19 a promising target in myeloma that we have begun to molecular development for.
Methods: We performed an in-silico molecular docking based screen of >10,000 small molecules against PHF19 Tudor domain using a previously identified PHF19 binding compound (UNC7242) as a scaffold. The top 100 compounds were screened using an MTS assay in common myeloma cell lines (8226, KMS11, and MM1S). The top two from this screen (abbreviated: IUSM1–2) and UNC7242 were tested alone and in combination with bortezomib in MM1S, OPM-2, and OPM-2 teclistamab-resistant (OPM-2-TCE) myeloma cell lines using an MTS assay. Mechanistic studies are ongoing by RNA-seq and ATAC-seq in MM1S, OPM-2, and OPM-2-TCE cells after 6 hours treatment with DMSO, IUSM1, UNC7242, bortezomib, IUSM1–bortezomib, UNC7242–bortezomib, tazematostat (EZH2 inhibitor), and tazematostat–bortezomib at 50 nM bortezomib and 25 µM UNC/tazematostat.
Results: We identified a previously described PHF19 inhibitor (UNC7242) and generated additional candidate molecules by in silico screening. Using this screen we were able to identify additional PHF19-targeting molecules with improved potency. Single-agent molecules targeting PHF19 produced modest reductions in viability at clinically relevant concentrations (at 50 µM: IUSM1 reduced viability by ~50%, IUSM2 by ~30%, and UNC7242 by ~15% at 36 hours). Across doses, combining PHF19 inhibitors with bortezomib further decreased viability compared with either agent alone, with IUSM1–bortezomib and UNC7242–bortezomib combinations showing the greatest effects in both MM1S and OPM cells. At 16 nM bortezomib, addition of IUSM1 (16 nM) decreased viability from ~95% to ~44% in MM1S, ~100% to ~60% in OPM-2, and ~100% to ~54% in OPM-2-TCE, while UNC7242 (16 nM)–bortezomib (16 nM) reduced viability to ~27% in MM1S, ~30% in OPM-2, and ~34% in OPM-2-TCE (n=4 replicates). Comparable enhancement was observed in OPM-2-TCE cells, suggesting that PHF19 inhibition can augment bortezomib response even in a treatment-exposed, teclistamab-resistant TCE context.
Conclusion: We have previously identified relapse-associated myeloma cells via deep learning-based risk inference and epigenetic mechanisms within these cells that may be driving their resistance. Based on these mechanisms, we have found a potential therapeutic target within these cells, an epigenetic regulator called PHF19. Screening results of PHF19-targeting molecules have shown that PHF19 is a progression-associated epigenetic vulnerability in multiple myeloma. Pharmacologic PHF19 inhibition enhances bortezomib activity, including in teclistamab-resistant cells, supporting further development of PHF19-directed therapeutic strategies.
I added the additional cell lines.
DISCLOSURES
Christopher Schorr, BS, BSc: No relevant conflicts of interest to declare.